More on AQST
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.38 |
|
|||
| Open | $4.38 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $4.50 | ||||
| Day Low | $4.24 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,698,300 | ||||
- Form 8-K Aquestive Therapeutics, For: Apr 22
- Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
- Piper Sandler Starts Aquestive Therapeutics (AQST) at Overweight, 'he risk/reward profile associated with AQST shares is attractive'
- Aquestive Therapeutics Inc. (AQST) Files $250M Mixed Shelf
- Form S-3 Aquestive Therapeutics,
- Form SC 13G Aquestive Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
- Form 8-K Aquestive Therapeutics, For: Apr 01
- Aquestive Therapeutics Inc. (AQST) Appoints Abigail Jenkins to its Board
- Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
- Raymond James Starts Aquestive Therapeutics (AQST) at Outperform
Entities mentioned with AQST
- FDA | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- S3 | View Related Stories »
- H.C. Wainwright | View Related Stories »
- BMO Capital | View Related Stories »
- Sanford C. Bernstein | View Related Stories »
- RBC Capital | View Related Stories »
- Show More...
